Results 231 to 240 of about 83,254 (357)

Comparative short-term efficacy of Janus kinase 1 inhibitors and anti-interleukin-13 antibodies in atopic dermatitis: a retrospective cohort analysis based on real-world data [PDF]

Emi Sato, Naoko Obonai, Mayuko Iwata, Kotaro Ito, Shinichi Imafuku   +4 more
openalex   +1 more source

When, which and how to switch: Navigating JAK inhibitors in myelofibrosis

British Journal of Haematology, EarlyView.
Navigating choice of JAK inhibitor (JAKi) therapy for patients with myelofibrosis who are JAKi‐naïve and for those who have previously been treated with a JAKi.
Jennifer O'Sullivan, Imran Omerdeen, Bethan Psaila   +2 more
wiley   +1 more source

Topical JAK (Janus Kinase) Inhibitor Therapy for Chronic External Otitis in Atopic Dermatitis: A Case Report. [PDF]

Cureus
Hirano K, Hirano Y, Yu M, Tei Y, Shimane T.   +4 more
europepmc   +1 more source

Changes in NK Cells and Exhausted Th Cell Phenotype in RA Patients Treated with Janus Kinase Inhibitors: Implications for Adverse Effects [PDF]

Juan José Fernández-Cabero, Carmen Lasa-Teja, David San Segundo, Alejandra Comins‐Boo, Juan Irure‐Ventura, Daniel Rivera, J. L. Martín-Varillas, Cristina Mata, Montserrat Santos, Elena Aurrecoechea, Ricardo Blanco, Marcos López‐Hoyos   +11 more
openalex   +1 more source

Hypomethylating agents in vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic syndrome (VEXAS): A systematic review

British Journal of Haematology, EarlyView.
Summary VEXAS syndrome (vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic) is an X‐linked, systemic, haemato‐inflammatory syndrome caused by somatic mutations in the UBA1 gene. No standardized treatment guidelines exist, but evidence is emerging that treatment with hypomethylating agents (HMAs) can induce improvement of the inflammatory symptoms,
Fieke W. Hoff, Roochi Trikha, Emma M. Groarke, Bhavisha A. Patel   +3 more
wiley   +1 more source

Acute graft versus host disease postliver transplant with mucocutaneous manifestations and pancytopenia: Remission with Janus kinase inhibitor. [PDF]

JAAD Case Rep
Mendoza R, Liu L, Sam A, Abdel-Azim H, Greas M, Dao H.   +5 more
europepmc   +1 more source

Targeting MCL‐1 and MAPK overcomes venetoclax resistance in FLT3‐ITD‐positive AML cells harbouring activating PTPN11 (SHP‐2) mutations

British Journal of Haematology, EarlyView.
Summary Venetoclax (VEN)‐based therapies have improved the treatment of acute myeloid leukaemia (AML); however, the emergence of resistance remains a major limitation. Mutations in protein tyrosine phosphatase (PTP) non‐receptor type 11 (PTPN11) and FMS like tyrosine kinase 3 with internal tandem duplication (FLT3‐ITD) are common in resistant patients ...
Maximilian Fleischmann, Ole Hansen, Diana Voigtländer, Julia Bechwar, Lenny‐Joseph Schwietzer, Sanja Bahr, Ulf Schnetzke, Mike Fischer, Florian H. Heidel, Tina M. Schnöder, Jörg P. Müller, Andreas Hochhaus, Sebastian Scholl   +12 more
wiley   +1 more source

Bone Mineral Density During Treatment with The Janus Kinase Inhibitor Baricitinib in Patients with Rheumatoid Arthritis: A Monocentric Observational Study. [PDF]

Calcif Tissue Int
Schulz N, Asendorf T, van Wijnen P, Wilhelmi T, Müller-Ladner U, Lange U, Klemm P.   +6 more
europepmc   +1 more source

Cytokine Milieu Relevant to Atopic Dermatitis Enhances Epidermal Trypsin‐Like Serine Protease Activity, Which Is Pharmacologically Suppressed in Human Keratinocytes

The Journal of Dermatology, EarlyView.
Shiori Onishi, Yohei Yasutomi, Onon Tsedendorj, Shin Morizane   +3 more
wiley   +1 more source

Opioids in breast cancer: Between analgesia and modulation of tumour progression

British Journal of Pharmacology, EarlyView.
Preclinical investigations consistently demonstrate that activation of μ‐opioid receptors and δ‐opioid receptors promote proliferation, migration, angiogenesis, epithelial‐mesenchymal transition, acquisition of cancer stem cell phenotypes, and chemoresistance.
Marianna Ciwun, Anna Tankiewicz‐Kwedlo, Dariusz Pawlak   +2 more
wiley   +1 more source